AMH specifically targets neuronal AMHR2 to modulate the progression of polycystic ovary syndrome
BMC Endocrine Disorders · 2026
DOI: 10.1186/s12902-025-02130-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift BMC Endocrine Disorders, 2026. Verfasst von Kaiming Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang, 150040, China. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Anti-Mullerian Hormone, Receptors, Transforming Growth Factor beta, Receptors, Peptide. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Polycystic ovary syndrome (PCOS) is a prevalent reproductive endocrine disorder among women of childbearing age, characterized by elevated serum anti-Müllerian hormone (AMH) levels as a key biomarker. This study primarily investigates the tissue-specific expression of AMHR2 (the receptor for AMH) and its mechanistic role in PCOS pathogenesis. METHODS: In this study, we employed a two-phase experimental approach to investigate the tissue-specific roles of AMHR2 in PCOS pathogenesis. First, we established extra-ovarian (Ex-AMHR2) and intra-ovarian (In-AMHR2) AMHR2 expression models through reciprocal ovarian transplantation between wild-type (WT) and conventional AMHR2 knockout (AMHR2−/−) female mice. Second, we systematically compared tissue-specific effects using conditional knockout models targeting either neuronal (Neur-AMHR2−/−) or ovarian (Ovary-AMHR2−/−) AMHR2 expression. All experimental groups received standardized AMH intervention (0.12 mg/kg, i.p., twice weekly for 4 weeks). Comprehensive evaluations included: (1) reproductive cyclicity monitoring and ovarian index calculation; (2) ELISA quantification of serum AMH, LH, FSH, T, E1, and E2 levels with derived hormonal ratios; (3) histopathological assessment of ovarian morphology via H&E staining with follicular enumeration; and (4) molecular analyses of oocyte quality markers (GDF9, BMP15) at both protein (Western blot) and mRNA (qPCR) levels. This integrated experimental paradigm enabled multi-dimensional characterization of compartmentalized AMHR2 signaling in PCOS development. RESULTS: By comparing mice with intraovarian and extraovarian expression of AMHR2, we discovered that the Ex-AMHR2 + AMH group exhibited significantly higher serum AMH levels than the In-AMHR2 + AMH group, along with hormonal profiles more consistent with PCOS pathology. Histological (H&E staining) analysis revealed severe follicular atresia, disorganized granulosa cell layers, and impaired luteal development in the Ex-AMHR2 + AMH group, further corroborated by reduced protein and mRNA expression of oocyte quality markers (GDF9, BMP15). Subsequent tissue-specific studies on AMHR2 reveal that the Neur-AMHR2−/−+AMH group demonstrated restored estrous cyclicity, improved serum levels of AMH and related hormones, compared with Ovary-AMHR2−/−+AMH group, indicating attenuated PCOS symptoms. Consistently, H&E staining and GDF9/BMP15 expression (protein & mRNA) confirmed enhanced oocyte quality in Neur-AMHR2−/− mice, reinforcing the central role of neuronal AMHR2 in mediating AMH-induced ovarian dysfunction. CONCLUSION: Neuronal AMHR2 serves as the specific binding site for AMH, and the neuronal AMH/AMHR2 signaling pathway contributes to PCOS pathogenesis by disrupting HPO axis hormone secretion and interfering with cyclic follicular development. CLINICAL TRIAL NUMBER: Not applicable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Heilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang, 150040, China.
- Department of Traditional Chinese Medicine, Huangdao District People's Hospital, Qingdao, Shandong, 266400, China.
- Department of Gynecology, The Second Affiliated Hospital of Tianjin University of TCM, Tianjin, 300250, China.
- Department of Gynaecology and Obstetrics, Shunyi Hospital of Beijing Hospital of Traditional Chinese Medicine, Beijing, 101300, China.
- Department of Gynecology II, The First Affiliated Hospital of Heilongjiang, University of Traditional Chinese Medicine, No.26, Heping Road, Xiangfang District, Harbin, Heilongjiang, 150040, China.
- Department of Gynecology II, The First Affiliated Hospital of Heilongjiang, University of Traditional Chinese Medicine, No.26, Heping Road, Xiangfang District, Harbin, Heilongjiang, 150040, China. kuanghongying1010@163.…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wu, K., Sun, C., Din, N., Guo, J., Li, J., Pan, Z., Wang, Y., Sun, M., & Kuang, H. (2026). AMH specifically targets neuronal AMHR2 to modulate the progression of polycystic ovary syndrome. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-025-02130-9
Vancouver
Wu K, Sun C, Din N, Guo J, Li J, Pan Z, et al. AMH specifically targets neuronal AMHR2 to modulate the progression of polycystic ovary syndrome. BMC Endocrine Disorders. 2026. doi:10.1186/s12902-025-02130-9
BibTeX
@article{Wu2026,
author = {Wu, Kaiming and Sun, Chang and Din, Ning and Guo, Jinqian and Li, Jing and Pan, Zimeng and Wang, Ying and Sun, Miao and Kuang, Hongying},
title = {AMH specifically targets neuronal AMHR2 to modulate the progression of polycystic ovary syndrome},
journal = {BMC Endocrine Disorders},
year = {2026},
doi = {10.1186/s12902-025-02130-9}
}
EUVIMED